Haibo Zhang
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC (NCT05027100) | Haibo Zhang | 2021-09-30 |
Track Haibo Zhang automatically
Every clearance here is in the API, with alerts when new ones post.